Robert J Grady

US Patent:

53025989, Apr 12, 1994

Filed:

Jul 7, 1992

Appl. No.:

7/910714

Inventors:

Allen B. Clarkson - New York NY
Robert W. Grady - Kinnelon NJ

Assignee:

New York University - New York NY

International Classification:

A61K 31505
A61K 3142
A61K 31155

US Classification:

514275

Abstract:

The present invention provides methods for treating and preventing the onset of Pneumocystis carinii pneumonia (PCP) comprising administering to a mammal in need of such treatment or prevention an effective amount of a pharmaceutically acceptable iron chelator. This invention also provides a method for treating or preventing the onset of PCP comprising administering to a mammal in need of such treatment or prevention a composition comprising the following components: (a) a pharmaceutically acceptable iron chelator; (b) a compound selected from trimethoprim/sulfamethoxazole and pentamidine; and (c) a pharmaceutically compatible carrier or diluent, wherein the amounts of said component (a) and said component (b) in combination are effective in treating said pneumonia. Also provided is a composition for the treatment or prevention of PCP.

US Patent:

58495878, Dec 15, 1998

Filed:

Jun 9, 1995

Appl. No.:

8/488811

Inventors:

Robert Walter Grady - Kinnelon NJ
Axel Hanauske - Wolratshausen, DE
Linda Andrus - New York NY
Paul Szabo - Linden NJ

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

C12N 508

US Classification:

4353723

Abstract:

The present invention is directed to methods which employ inhibition of the post-translational hypusine formation in the intracelluar protein eIF-5A, for the purpose of suppressing infections by viruses that parasitize eIF-5A so as to promote their own replication. Intentional inhibition of the post-translational formation of hypusine in infected host cells with compounds generically termed `hypusine inhibitors` not only selectively suppresses the production of viral proteins and of infectious viral particles, but also causes, particularly after hypusine inhibitor withdrawal, apoptosis in such virally-infected cells. Each of these methods, respectively, involves administering, to eukaryotic cells, tissues, or individuals, an agent which blocks the post-translational intracellular formation of hypusine, in an amount sufficient to: suppress biosynthesis of bioactive eIF-5A, suppress translational interaction of eIF-5A with viral elements of nucleic acid and/or protein structure, inhibit biosynthesis of viral proteins of Rev-dependent lentiviruses or of viruses dependent on interaction of eIF-5A with viral elements of nucleic acid and/or protein structure, inhibit replication of Rev-dependent lentiviruses or of viruses dependent on interaction of eIF-5A with viral elements of nucleic acid and/or protein structure, and induce apoptosis of virally-infected cells. This agent can be a compound of Formulae I or II and derivatives thereof as follows: ##STR1## R. sub. 1, R. sub. 2, R. sub. 3, and R. sub. 4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

US Patent:

54629691, Oct 31, 1995

Filed:

Feb 4, 1994

Appl. No.:

8/192404

Inventors:

Allen B. Clarkson - New York NY
Robert W. Grady - Kinnelon NJ

Assignee:

New York University - New York NY

International Classification:

A61K 3119
A61K 31155

US Classification:

514575

Abstract:

The present invention provides methods for treating and preventing the onset of Pneumocytis carinii pneumonia (PCP) comprising administering to a mammal in need of such treatment or prevention an effective amount of a pharmaceutically acceptable iron chelator. This invention also provides a method for treating or preventing the onset of PCP comprising administering to a mammal in need of such treatment or prevention a composition comprising the following components: (a) a pharmaceutically acceptable iron chelator; (b) a compound selected from trimethoprim/sulfamethoxazole and pentamidine; and (c) a pharmaceutically compatible carrier or diluent, wherein the amounts of said component (a) and said component (b) in combination are effective in treating said pneumonia. Also provided is a composition for the treatment or prevention of PCP.

US Patent:

59655852, Oct 12, 1999

Filed:

May 30, 1997

Appl. No.:

8/866998

Inventors:

Timothy A. McCaffrey - New York NY
Robert Walter Grady - Kinnelon NJ

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A01N 4340

US Classification:

514348

Abstract:

The present invention relates to a method of treating a patient with a fibrotic or fibroproliferative disorder and a method of suppressing formation of collagen and collagen-like substances or biosynthesis of procollagen in living systems by administering to a patient or living system, respectively, an effective amount of a compound of Formulae (I) or (II) and derivatives thereof: ##STR1## R. sub. 1, R. sub. 2, R. sub. 3, and R. sub. 4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

US Patent:

57894264, Aug 4, 1998

Filed:

Jan 20, 1995

Appl. No.:

8/377137

Inventors:

Timothy A. McCaffrey - New York NY
Robert Walter Grady - Kinnelon NJ

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A01N 4340

US Classification:

514348

Abstract:

The present invention relates to a method of treating a patient with a fibrotic or fibroproliferative disorder and a method of suppressing formation of collagen and collagen-like substances or biosynthesis of procollagen in living systems by administering to a patient or living system, respectively, an effective amount of a compound of Formulae (I) or (II) and derivatives thereof: ##STR1## R. sub. 1, R. sub. 2, R. sub. 3, and R. sub. 4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

US Patent:

60807660, Jun 27, 2000

Filed:

Dec 16, 1997

Appl. No.:

8/991124

Inventors:

Timothy A. McCaffrey - New York NY
Robert Walter Grady - Kinnelon NJ

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 3144

US Classification:

514348

Abstract:

The present invention relates to a method of treating a patient with a fibrotic or fibroproliferative disorder and a method of suppressing formation of collagen and collagen-like substances or biosynthesis of procollagen in living systems by administering to a patient or living system, respectively, an effective amount of a compound of Formulae (I) or (II) and derivatives thereof: ##STR1## R. sub. 1, R. sub. 2, R. sub. 3, and R. sub. 4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

US Patent:

60462191, Apr 4, 2000

Filed:

Dec 16, 1997

Appl. No.:

8/991913

Inventors:

Timothy A. McCaffrey - New York NY
Robert W. Grady - Kinnelon NJ

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A01N 4340

US Classification:

514348

Abstract:

The present invention relates to a method of treating conditions mediated by collagen formation together with cell proliferation by administering to a patient or living system an effective amount of a compound of Formulae (I) or (II) and derivatives thereof: ##STR1## R. sub. 1, R. sub. 2, R. sub. 3, and R. sub. 4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

US Patent:

59655860, Oct 12, 1999

Filed:

Dec 16, 1997

Appl. No.:

8/991758

Inventors:

Timothy A. McCaffrey - New York NY
Robert Walter Grady - Kinnelon NJ

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A01N 4340
A61K 3144

US Classification:

514348

Abstract:

The present invention relates to a method of treating a patient with a fibrotic or fibroproliferative disorder and a method of suppressing formation of collagen and collagen-like substances or biosynthesis of procollagen in living systems by administering to a patient or living system, respectively, an effective amount of a compound of Formulae (I) or (II) and derivatives thereof: ##STR1## R. sub. 1, R. sub. 2, R. sub. 3, and R. sub. 4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.